Insights
Insights From Our Experts
Articles
Point of Attack: Developing a Targeted Oncology Account Engagement Strategy and Tactical Platform
Key account management (KAM) is a more innovative approach to pharmaceutical sales and account engagement. KAM promises to deliver long-term, mutually beneficial partnerships between biopharmaceutical manufacturers and healthcare systems and provider practices (aka target accounts). Pharmaceutical…
Reimbursement Landscape for Digital Medicine Continues to Advance with CMS
The Centers for Medicare and Medicaid Services (CMS) recently announced several new payment and coding proposals that, once finalized, would recognize and advance the use of digital diagnostic and therapeutic modalities. In this week’s update, we…
Connectivity Between Field Reimbursement Managers and Patient Services: The Missing Link to Efficiency
EVERSANA’s Rich Heddens, Senior Vice President, Payer Strategy & Execution, and Matthew Baniak, Vice President, Client Delivery & Excellence, discuss the importance of connectivity between Field Reimbursement Managers (FRMs) and Patient Services. Disparate information, antiquated systems…
Innovative Payer Strategies Demand Innovative NAM Strategies
EVERSANA’s Rich Heddens, Senior Vice President, Payer Strategy & Execution, and Dino Tsamparlis, Vice President, Market Access, discuss how innovative payer strategies call for innovative National Account Manager (NAM) strategies. The industry is facing unique challenges…
Plasma derived medicinal products – What is the way forward?
Content for this article was contributed by the EVERSANA Asia Pacific team. Plasma-derived products have a long history of providing benefits, especially in fractions addressing coagulation. Plasma is a rich biological substance and one of the…
Single-Cell Multiomics: Opportunities, Challenges, and the Evolving Business Model
Content for this article was contributed by EVERSANA’s Asia Pacific team. Single Cell Multiomics is a Fast-Growing Market Space with a Wide Range of Applications Single cell multiomics is a new and exciting space in the…
Successful Early-Stage Out-Licensing Requirements
The attention on vaccines during the COVID-19 crisis highlighted the role of biotech companies and positive sentiment increased for the sector. In 2021, a record number of biotech (100+) companies went public and listed companies soared…
EVERSANA’s Value & Evidence Team’s Work Tops List of Most Read Articles in 2021 in Journal of Comparative Effectiveness Research
If you work in the field of Health Economics and Outcome Research (HEOR) in the life sciences industry, you know just how valuable the Journal of Comparative Effectiveness Research (JCER) is. The publication features peer-reviewed studies…
Social Determinants of Health – What Pharma Can Do!
The US Department of Health and Human Services defines Social Determinants of Health (SDoH) as conditions in the places where people live, learn, work, and play that affect a wide range of health risks and outcomes.1…
Case Study: Leveraging machine learning models in patient identification and behavior prediction for rare disease indications
When a mid-sized pharmaceutical company was challenged with trial and adoption of their immune thrombocytopenia (ITP) drug due to fierce competition and the lingering impact of COVID-19, they turned to the team of data and analytics…